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In 2012, a 33-year-old woman was diagnosed with relapsing-remitting MS (RRMS) after
fulﬁlling McDonald criteria and careful exclusion of other diﬀerential diagnoses. Five years later
(EDSS 1), she changed her disease-modifying therapy after side eﬀects to betaferon (ﬂu-like
symptoms) and dimethyl fumarate (erythema and pruritus) to daclizumab. Twomonths after 2
applications of 150 mg daclizumab, she developed a self-limiting rash (ﬁgure 1A), followed by
fever, headaches, meningismus, photophobia, nausea, paraesthesia, and itching of her upper
body 1 month later. Blood test showed decreased lymphocyte counts of 1.7/μL (17.1%) and
increased eosinophil granulocytes of 1.5/μL (15.1%). CSF analysis revealed pleocytosis of 570/
μL (1.8% eosinophilic granulocytes) and an initially negative, but 2 weeks later marked in-
trathecal immunoglobulin synthesis (IgM 85%, IgA 43%, and IgG 38%). MRI showed peri-
ventricular contrast-enhancing lesions and a multisegmental cervical myelitis (C1–4). After 10
days, she further deteriorated by severe infratentorial edema with compression of the fourth
ventricle and obstructive hydrocephalus (ﬁgure 1, B–F). At admission to our hospital, she
obtained an external ventricle drainage showing normal opening pressure. Two days later, she
had sudden increase in intracranial pressure requiring intubation and emergency decom-
pressive surgery of the posterior fossa. Increased intracranial pressure (up to 40 mmHg) due to
global brain edema and subsequently complicated by a postoperative bleeding into the right
frontal lobe after a brain biopsy (see below) was controlled by CSF drainage, deep analgose-
dation, dexamethasone, and osmotherapy. The atypical clinical picture with brain edema,
rhombenecephalitis, and high CSF cell count was incompatible with MS relapse as initially
suggested by the periventricular lesions and cervical myelitis. Because careful examinations
revealed no other autoimmune or infectious diseases, we initially treated polypragmatically with
aciclovir/ganciclovir, ceftriaxone/ampicillin, voriconazole/posaconazole, and IV immunoglo-
bulins. Brain biopsies of the right frontal lobe, cerebellum, and cerebellar leptomeninges
showed inﬂammatory demyelinating lesions with pronounced inﬂammation, numerous T cells,
eosinophils, plasma cells, and an eosinophilic and lymphoplasmacellular meningitis (ﬁgure 1,
G–J). We diagnosed the patient with CNS manifestation of daclizumab-induced DRESS (drug
reaction with eosinophilia and systemic symptoms) since 6 of 7 Registry of Severe Cutaneous
Adverse Reaction Criteria (RegiSCAR)1 for DRESS were fulﬁlled (positive: hospitalization,
reaction suspected to be drug-related, fever >38°C, skin rash, internal organ involvement, blood
eosinophilia; negative: lymphadenopathy). Accordingly, the patient was treated with high-dose
IV methylprednisolone (5 days with 1 g each) and 6 cycles of plasma exchange, followed by 1
mg/kg oral prednisolone with subsequent tapering. Thereafter, the patient improved dra-
matically and could be extubated 2 weeks after disease exacerbation. Postoperative disease
course was complicated by wound infection, bacterial meningitis, persisting CSF eﬀusion, and
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obstructive hydrocephalus that required a ventriculoper-
itoneal shunt. Four months later, neurologic syndromes with
tetraparesis, choreoathetosis, cerebellar ataxia, and cognitive
dysfunctions had regressed substantially (EDSS 3.5).
Discussion
Daclizumab is approved for RRMS therapy since it revealed
eﬃcacy by reducing relapse rates andMRI lesion load.2 It binds
to the interleukin-2 receptor and leads to reduction of activated
T cells and regulatory T cells and expansion of natural killer
cells.3,4 Common daclizumab side eﬀects comprise infections
(59%), cutaneous (33%), gastrointestinal (25%), and hepatic
disorders (16%).5 Until recently, no persuasive evidence of
DRESS existed in daclizumab-treated patients,5 especially not
with CNS manifestation. Several drugs including immuno-
modulators can trigger DRESS presenting with skin eruption,
hematologic abnormalities, lymphadenopathy, and internal
organ involvement.6 DRESS usually develops with a latency of
2 to 12 weeks after drug exposure showing often a prolonged
course and can be lethal in;10% of cases. The pathogenesis of
DRESS remains unclear, but reactivation of herpesviridae and
pharmacogenomic association with certain human leukocyte
antigen haplotypes may cause the increased susceptibility to
DRESS and its associated drug-speciﬁc immune dysfunction.6
CNS DRESS is extremely rare and typically presents with
a vasculitis-like pattern.7
Core symptoms of our patient comprised fever, skin rash,
blood eosinophilia, and eosinophilic meningoencephalo-
myelitis. We diagnosed our patient with daclizumab-induced
DRESS with CNS manifestation since a recent publication
presented 2 further cases of daclizumab-induced DRESS in
MS.8 In line with our case, these patients showed similar
clinical symptoms, fulﬁlled RegiSCAR criteria of DRESS, and
were characterized by the same unique histopathologic ﬁnd-
ings with demyelinating lesions consisting of lympho-
plasmacellular and eosinophilic inﬁltrates and a vasculitic-like
pattern. Other diﬀerential diagnosis like parasitosis or neu-
romyelitis optica (NMO) was excluded. NMO can show
eosinophilic inﬁltrates in demyelinating lesions, but further
NMO characteristics like aquaporin-4 loss, dystrophic astro-
cytes, or loss of oligodendrocytes were missing, and
aquaporin-4 antibody testing was negative in our patient.
Although DRESS criteria were formally fulﬁlled, it remains
open whether DRESS alone best explains pathophysiology or
whether other/further mechanisms are involved in
daclizumab-induced immune dysfunction. In contrast to
Figure Clinical presentation of daclizumab side effects with skin rash and meningoencephalomyelitis
(A) Skin rash of the neckline. (B and C) MRI shows multiple actively contrast-enhancing MS-like lesions with distinct perifocal edema. (D and E) Additionally
diffuse cerebellar edema is present accompanied by infratentorial leptomeningeal enhancement indicative of meningeal and cerebellar inflammation.
Resulting mass effect and occlusive hydrocephalus required suboccipital decompression (E). Also note simultaneous cervical cord inflammatory lesion. (F)
Complete resolution of perifocal edema after disease remission. Note the right frontal hemorrhagic biopsy defect. (G–J) Biopsies of cerebellar meninges (G)
and a right frontal lesion (H–J) show apronounced inflammatory infiltrate. HE staining depictsmeningitis with numerous T cells, plasma cells, and eosinophilic
granulocytes (G). Histology of the right frontal lesion reveals a demyelinated lesion (H). Again, dominant inflammation, consisting of CD4- and CD8-positive
T cells (I, anti-CD8), CD138-positive plasma cells (J, anti-CD138), and eosinophilic granulocytes, is evident. Inflammatory cells densely infiltrate vessel walls,
resembling vasculitis. In addition, pronounced parenchymal inflammation is evident. HE = hematoxylin/eosin, LFB/PAS = luxol fast blue/periodic acid-Schiff.
Scale bars: G = 100 μm, H = 1 mm, and I (valid for I and J) = 200 μm.
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regular DRESS that barely aﬀects the CNS, daclizumab-
induced DRESS seems to occur predominantly within the
CNS. The cause of this idiosyncratic drug reaction remains
speculative, but a certain genetic, viral, and autoimmune
susceptibility in the context of MS has to be considered. At
least, a viral association (human herpes virus-6, cytomegalo-
virus, and Epstein-Barr virus) of DRESS was excluded in our
case.
Currently, 12 cases (including our patient) of autoimmune
encephalitis/encephalopathy after daclizumab therapy in MS
are known worldwide and led to voluntary withdrawal of
marketing authorization for daclizumab by the manufacturer
Biogen (press release from European Medicines Agency,
07.03.2018).9
Our ﬁndings suggest that early recognition of DRESS even
with CNS manifestations and swift treatment with steroids
and/or plasma exchange are essential to improve the long-
term outcome.
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